GlaxoSmithKline plc (LON:GSK)‘s stock had its “neutral” rating restated by stock analysts at J P Morgan Chase & Co in a research note issued to investors on Monday. They presently have a GBX 1,570 ($20.83) target price on the stock. J P Morgan Chase & Co’s price target would indicate a potential upside of 3.29% from the stock’s current price.

Several other equities analysts have also commented on GSK. Deutsche Bank AG set a GBX 1,610 ($21.36) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Thursday, September 21st. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline plc in a research report on Wednesday, September 20th. Berenberg Bank reissued a “buy” rating and set a GBX 1,835 ($24.34) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, September 19th. Bryan, Garnier & Co restated a “neutral” rating and issued a GBX 1,710 ($22.68) price objective on shares of GlaxoSmithKline plc in a report on Tuesday, September 19th. Finally, Jefferies Group LLC reduced their price objective on shares of GlaxoSmithKline plc from GBX 1,750 ($23.21) to GBX 1,675 ($22.22) and set a “buy” rating on the stock in a report on Monday, September 18th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the stock. GlaxoSmithKline plc has an average rating of “Hold” and a consensus target price of GBX 1,691.86 ($22.44).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1520.00 on Monday. The company’s market cap is GBX 74.30 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,444.00 and a 1-year high of GBX 1,745.56. The stock’s 50 day moving average is GBX 1,496.17 and its 200 day moving average is GBX 1,592.59.

COPYRIGHT VIOLATION NOTICE: This story was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-stock-rating-reaffirmed-by-j-p-morgan-chase-co/1606418.html.

In other GlaxoSmithKline plc news, insider Patrick Vallance bought 861 shares of GlaxoSmithKline plc stock in a transaction on Friday, July 14th. The shares were bought at an average cost of GBX 1,618 ($21.46) per share, for a total transaction of £13,930.98 ($18,478.55). Also, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction on Wednesday, July 26th. The shares were acquired at an average price of GBX 1,599 ($21.21) per share, for a total transaction of £36,249.33 ($48,082.41). Insiders purchased 3,152 shares of company stock valued at $5,055,023 in the last 90 days.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.